Isomorphic Labs, which hasn’t yet disclosed a molecule or reached the clinic, breaks the recent trend of investors putting ...
Three pharma CEOs joined the $30 million compensation club in 2025 but Eli Lilly’s David Ricks exceeded his nearest peer by ...
The FDA's decision last year to make complete response letters public provides new insight into why therapies sometimes fail ...
MacroGenics is selling the manufacturing plant to Bora, a Taiwan-based CDMO, to raise cash to support the progress of its drug development pipeline. Bora Pharmaceuticals has struck a deal to buy ...
The widely covered impending ouster of FDA Commissioner Marty Makary not long after the exit of controversial biologics head ...
Partner Therapeutics announced last week that the FDA had granted Bizengri a Commissioner’s National Priority Voucher to ...
New guidelines from two leading medical associations suggest that efforts to reduce bad cholesterol should focus on ...
(Image source: https://gisaid.org/rsv-subtypes-dashboard) ...
Gilead is laying off Arcellx employees in California and Maryland, with some cuts effective this year and the remainder ...
The FDA turned away Ebvallo in January, taking issue with the design of the registrational trial. In a recent meeting, however, the agency agreed that the study could in fact support the cell ...
After a 12-month period that saw the Belgian biotech consider a spinout, swap out CEOs, and enter a three-way acquisition agreement involving Ouro Medicines, Galapagos now has a new moniker.
Acting Center for Drug Evaluation and Research Director Tracy Beth Høeg reportedly disagreed with staff who wanted to approve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results